Skip to site menu Skip to page content

Genesis receives approval in China for laparoscopic surgical device

South Korean company LivsMed developed the ArtiSential device.

RanjithKumar Dharma July 07 2023

Genesis MedTech has secured approval from China's National Medical Products Administration for the launch of the laparoscopic surgical device, ArtiSential, in the country.

South Korean medical device company LivsMed developed the ArtiSential device and in 2021, Genesis MedTech entered an exclusive distribution agreement with LivsMed to launch this device into the Chinese market.

The device mimics the surgeon's wrist and finger movements, offering several clinical advantages that improve surgical precision and outcomes.

For enabling full access to narrow surgical sites, the double-joint end-effector of the device facilitates freedom of movement.

Designed to operate on a fully mechanical structure with tactile feedback conduction, the device provides a realistic feel of the endoscopic operation to the surgeon.

Furthermore, it offers a full range of customised end-effectors and can meet several clinical needs.

ArtiSential was launched in Korea in 2018 and in the US market the following year.

The device is already marketed in various countries, including the UK, Germany, Australia and Japan.

With the launch of ArtiSential, surgeons in China will be equipped with an instrument to provide better care to their patients.

Headquartered in Singapore, Genesis MedTech supplies multi-therapy medical device products in emerging markets.

Created by Dr Jung Joo Lee, LivsMed focuses on transforming the capabilities of minimally invasive surgery and improving surgical outcomes.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close